2-(1-戊炔-1-基)-1,3-噻唑 | 329202-25-7

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 中文名称: 2-(1-戊炔-1-基)-1,3-噻唑
• 英文名称: 2-(1-Pentynyl)-1,3-thiazole
• 英文别名: 2-pent-1-ynyl-1,3-thiazole
• CAS: 329202-25-7
• 化学式: C₈H₉NS
• 分子量: 151.232
• InChiKey: ZLQNIRDQANOVNB-UHFFFAOYSA-N

物化性质

• 沸点：
  233.8±23.0 °C(Predicted)
• 密度：
  1.09±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.7
• 重原子数：
  10
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.38
• 拓扑面积：
  41.1
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  2-(1-戊炔-1-基)-1,3-噻唑 在 dimethyltitanocene zinc chloride diethyl ether 、 sodium cyanoborohydride 作用下， 以 四氢呋喃 、 乙醚 、 甲苯 为溶剂， 反应 21.0h， 生成 (1-Thiazol-2-ylmethyl-butyl)-p-tolyl-amine
  参考文献：
  名称：

  2-芳基乙胺衍生物的高度灵活合成

  摘要：

  描述了一种新的、高度灵活的合成 2-芳基乙胺衍生物的方法。通过新的程序，可以从芳基卤化物、末端炔烃和伯胺三个步骤中以高度多样性合成目标化合物。反应序列开始于钯催化的芳基卤化物和末端炔烃的偶联（Sonogashira 偶联）。随后在 Cp2TiMe2 催化下对获得的烷基（芳基）炔烃在 2 位区域选择性地进行加氢胺化，从而获得 α-芳基酮亚胺。最终用 NaBH3CN/ZnCl2·Et2O 还原生成所需的 2-芳基乙胺衍生物。(© Wiley-VCH Verlag GmbH, 69451 Weinheim, Germany, 2002)

  DOI：

  10.1002/1099-0690(200204)2002:7<1213::aid-ejoc1213>3.0.co;2-g
• 作为产物：
  描述：

  2-溴噻唑 、 1-戊炔 在 (1,1'-bis(diphenylphosphino)ferrocene)palladium(II) dichloride 、 copper(l) iodide 、 三乙胺 作用下， 以> 99 %的产率得到2-(1-戊炔-1-基)-1,3-噻唑
  参考文献：
  名称：

  铑催化[2+2+2]环加成中未活化内炔的相容性评估

  摘要：

  官能化的1,2,4,5-四取代苯在合成上很难或很难获得。 Rh 催化的二炔和内炔的 [2+2+2] 环加成为这些支架提供了一条看似简单的途径；然而，这在很大程度上仅限于带有活化（配位）官能团的炔烃，很少有未活化的炔烃。在这项工作中，我们公开了对使用未活化的内部炔烃的 Rh 催化的 [2+2+2] 环加成的评估，重点关注炔烃和二炔组分的结构多样性和相容性。该方法的局限性被揭示，特别大的炔烃和特定的官能团会发生副反应。此外，还证明了克级反应和催化剂回收/再利用的实用性。

  DOI：

  10.1055/a-2285-0007

文献信息

• Imidazolyl and pyrazolyl ethyne compounds
  申请人：Cosford D. Nicholas

  公开号：US20050085523A1

  公开（公告）日：2005-04-21

  In accordance with the present invention, there is provided a novel class of heterocyclic compounds. Compounds of the invention contain a substituted, unsaturated five, six or seven membered heterocyclic ring that includes at least one nitrogen atom and at least one carbon atom. The ring additionally includes three, four or five atoms independently selected from carbon, nitrogen, sulfur and oxygen atoms. The heterocyclic ring has at least one substituent located at a ring position adjacent to a ring nitrogen atom. This mandatory substituent of the ring includes a moiety (B), linked to the heterocyclic ring via a carbon-carbon double bond, a carbon-carbon triple bond or an azo group. The mandatory substituent is positioned adjacent to the ring nitrogen atom. Invention compounds are capable of a wide variety of uses. For example heterocyclic compounds can act to modulate physiological processes by functioning as agonists and antagonists of receptors in the nervous system. Invention compounds may also act as insecticides, and as fungicides. Pharmaceutical compositions containing invention compounds also have wide utility.

  根据本发明，提供了一类新型的杂环化合物。该发明的化合物包含一个取代的、不饱和的五、六或七元杂环环，其中至少包含一个氮原子和至少一个碳原子。该环另外包括三、四或五个独立选择的碳、氮、硫和氧原子。杂环环在至少一个邻近环氮原子的环位置上具有至少一个取代基。该环的强制性取代基包括一个通过碳-碳双键、碳-碳三键或偶氮基与杂环环相连的基团（B）。强制性取代基位于环氮原子的邻近位置。本发明的化合物能够具有各种用途。例如，杂环化合物可以通过作为神经系统受体的激动剂和拮抗剂来调节生理过程。本发明的化合物也可以作为杀虫剂和杀菌剂。含有本发明化合物的药物组合物也具有广泛的用途。
• Pyridazine, pyrimidine and pyrazine ethyne compounds
  申请人：Cosford D. Nicholas

  公开号：US20050043307A1

  公开（公告）日：2005-02-24

  In accordance with the present invention, there is provided a novel class of heterocyclic compounds. Compounds of the invention contain a substituted, unsaturated five, six or seven membered heterocyclic ring that includes at least one nitrogen atom and at least one carbon atom. The ring additionally includes three, four or five atoms independently selected from carbon, nitrogen, sulfur and oxygen atoms. The heterocyclic ring has at least one substituent located at a ring position adjacent to a ring nitrogen atom. This mandatory substituent of the ring includes a moiety (B), linked to the heterocyclic ring via a carbon-carbon double bond, a carbon-carbon triple bond or an azo group. The mandatory substituent is positioned adjacent to the ring nitrogen atom. Invention compounds are capable of a wide variety of uses. For example heterocyclic compounds can act to modulate physiological processes by functioning as agonists and antagonists of receptors in the nervous system. Invention compounds may also act as insecticides, and as fungicides. Pharmaceutical compositions containing invention compounds also have wide utility.

  根据本发明，提供了一类新型的杂环化合物。该发明的化合物包含一个取代的、不饱和的五、六或七元杂环环，其中至少包含一个氮原子和至少一个碳原子。该环另外包括三、四或五个独立选择的碳、氮、硫和氧原子。杂环环至少有一个取代基位于邻近环氮原子的环位置。该环的强制性取代基包括一个通过碳-碳双键、碳-碳三键或偶氮基与杂环环连接的基团（B）。强制性取代基位于环氮原子的邻近位置。本发明的化合物能够广泛用于各种用途。例如，杂环化合物可以通过作为神经系统受体的激动剂和拮抗剂来调节生理过程。本发明的化合物也可以作为杀虫剂和杀菌剂。含有本发明化合物的药物组合物也具有广泛的用途。
• Thiazolyl(pyridyl)ethyne compounds
  申请人：——

  公开号：US20030055247A1

  公开（公告）日：2003-03-20

  In accordance with the present invention, there is provided a novel class of heterocyclic compounds. Compounds of the invention contain a substituted, unsaturated five, six or seven membered heterocyclic ring that includes at least one nitrogen atom and at least one carbon atom. The ring additionally includes three, four or five atoms independently selected from carbon, nitrogen, sulfur and oxygen atoms. The heterocyclic ring has at least one substituent located at a ring position adjacent to a ring nitrogen atom. This mandatory substituent of the ring includes a moiety (B), linked to the heterocyclic ring via a carbon-carbon double bond, a carbon-carbon triple bond or an azo group. The mandatory substituent is positioned adjacent to the ring nitrogen atom. Invention compounds are capable of a wide variety of uses. For example heterocyclic compounds can act to modulate physiological processes by functioning as agonists and antagonists of receptors in the nervous system. Invention compounds may also act as insecticides, and as fungicides. Pharmaceutical compositions containing invention compounds also have wide utility.

  根据本发明，提供了一类新型的杂环化合物。该发明的化合物包含一个取代的、不饱和的五、六或七元杂环环，其中至少包含一个氮原子和至少一个碳原子。该环另外包括三、四或五个独立选择的碳、氮、硫和氧原子。杂环环在靠近环氮原子的环位置上至少有一个取代基。该环的强制性取代基包括一个通过碳-碳双键、碳-碳三键或偶氮基与杂环环相连的基团（B）。强制性取代基位于环氮原子的相邻位置。本发明的化合物具有各种用途。例如，杂环化合物可以通过作为神经系统受体的激动剂和拮抗剂来调节生理过程。本发明的化合物也可以作为杀虫剂和杀菌剂。含有本发明化合物的药物组合物也具有广泛的用途。
• Pyridine analogs as C5a antagonists
  申请人：Lachance Nicolas

  公开号：US20050277644A1

  公开（公告）日：2005-12-15

  The present invention provides novel compounds of Formula I which are antagonists of the C5a receptor. Compounds of the present invention are useful for the treatment of various C5a-mediated diseases and disorders; accordingly the present invention provides a method for the treatment of C5a-mediated diseases using the novel compounds described herein, as well as pharmaceutical compositions containing them.

  本发明提供了化合物I的新型化合物，这些化合物是C5a受体的拮抗剂。本发明的化合物对于治疗各种C5a介导的疾病和疾病非常有用；因此，本发明提供了一种使用本文所描述的新型化合物治疗C5a介导疾病的方法，以及含有这些化合物的药物组合物。
• [EN] HETEROCYCLIC COMPOUNDS AND METHODS OF USE THEREOF<br/>[FR] COMPOSES HETEROCYCLIQUES ET PROCEDES D'UTILISATION DE CEUX-CI
  申请人：MERCK & CO INC

  公开号：WO2001016121A1

  公开（公告）日：2001-03-08

  In accordance with the present invention, there are provided novel class of heterocyclic compounds and methods of use thereof. Compounds of the invention contain a substituted, unsaturated five, six or seven membered heterocyclic ring that includes at least one nitrogen atom and at least one carbon atom. At a ring position adjacent to a ring nitrogen atom, the heterocyclic ring has at least one substituent which includes a moiety, linked to the heterocyclic ring via an alkylene moiety, an alkynylene moiety or an azo group. Invention compounds are capable of a wide variety of uses including modulating physiological processes by functioning as agonists and antagonists of receptors in the nervous system, as insecticides, and as fungicides. The invention further provides methods of modulating the activity of excitatory amino acid receptors using a specifically defined class of heterocyclic compounds including the novel compounds referred to above. In one embodiment, there are provided methods of modulating metabotropic glutamate receptors. The present invention also discloses methods of treating disease using heterocyclic compounds. The invention further discloses methods of preventing disease conditions related to diseases of the pulmonary system, diseases of the nervous system, diseases of the cardiovascular system, diseases of the gastrointestinal system, diseases of the endocrine system, diseases of the exocrine system, diseases of the skin, cancer and diseases of the ophthalmic system. The invention also discloses pharmaceutically acceptable salt forms of the above-described heterocyclic compounds.

  根据本发明，提供了一类新型的杂环化合物及其使用方法。该发明的化合物包含一个取代的、不饱和的五、六或七元杂环环，其中至少包含一个氮原子和至少一个碳原子。在靠近环氮原子的环位置上，杂环环有至少一个取代基，包括一个官能团，通过烷基官能团、炔基官能团或偶氮基团连接到杂环环上。发明的化合物能够广泛应用，包括通过作为神经系统受体的激动剂和拮抗剂来调节生理过程，作为杀虫剂和杀菌剂。本发明还提供了使用特定定义的杂环化合物类来调节兴奋性氨基酸受体活性的方法，包括上述新型化合物。在一种实施例中，提供了调节代谢性谷氨酸受体的方法。本发明还揭示了使用杂环化合物治疗疾病的方法。本发明还揭示了预防与肺系统疾病、神经系统疾病、心血管系统疾病、胃肠系统疾病、内分泌系统疾病、外分泌系统疾病、皮肤疾病、癌症和眼科系统疾病相关的疾病状态的方法。本发明还揭示了上述杂环化合物的药物可接受的盐形式。